GLP-1 weight loss plateaus: what the science says vs. TikTok tips

What did @brijamz actually say?

The creator laid out three steps for breaking a GLP-1 weight loss plateau, defined as three to four weeks without scale movement while staying in a calorie deficit. Their advice: increase protein to protect muscle mass, try switching your injection site, and triple-check your calorie intake because "portion creep is real." They also flagged that if nothing works, talking to your provider about a dosage adjustment is worth considering.

The framing is practical and experience-based, which is refreshing compared to the usual hype around these medications. The creator isn't selling anything here. They're sharing what worked for them, which is a meaningful distinction. That said, personal experience is not the same as evidence, so let's look at what actually holds up.

Does the science back this up?

Mostly, yes, with one significant exception. The protein and calorie-tracking advice is well-supported. The injection site claim is where things get shakier.

On protein: preserving lean mass during a calorie deficit is a legitimate concern on GLP-1 therapy. A 2023 analysis by Wilding et al. in Diabetes, Obesity and Metabolism noted that semaglutide-driven weight loss includes a meaningful proportion of lean mass, which is consistent with most calorie-restriction weight loss. Higher protein intake is associated with attenuating muscle loss during energy restriction (Churchward-Venne et al., 2012, Nutrition and Metabolism). The metabolic rate argument, that losing muscle lowers your basal metabolic rate and thus shrinks your deficit, is textbook energy physiology and has been replicated across multiple diet studies.

On calorie tracking: the evidence for portion underestimation is overwhelming. Dhurandhar et al. (2015, International Journal of Obesity) documented systematic underreporting of calorie intake across populations. Suggesting a food diary for a week is genuinely sound advice.

On injection sites: the pharmacokinetics of subcutaneous semaglutide show some variability by site, but this has not been demonstrated to cause or resolve plateaus in clinical trials.

What did they get wrong (or right)?

The injection site tip is the weakest link here. The creator says "not every site is created equal for everybody" and implies that switching sites might restart weight loss. There is some pharmacokinetic data showing that subcutaneous absorption varies by site, with abdominal injections generally producing faster absorption than thigh or arm (Niskanen et al., 1991, Diabetic Medicine, for insulin, which has some parallel). However, for semaglutide specifically, Novo Nordisk's own prescribing information states that injection site does not significantly affect overall bioavailability. Attributing a plateau to injection site and expecting a site switch to break it is not supported by evidence. It's speculative at best.

What they got right is the calorie creep point. This is probably the most underrated issue in GLP-1 weight loss journeys. As appetite suppression becomes the new normal, people often stop tracking and quietly drift back to higher intake. The creator's suggestion to log food for a week is practical and evidence-backed.

The protein advice is also solid, though the creator doesn't quantify it. Current guidance from obesity medicine specialists generally suggests 1.2 to 1.6 grams per kilogram of body weight during active weight loss, but that's a conversation for a provider, not a TikTok tip.

What should you actually know?

Weight loss plateaus on GLP-1 medications are real and documented. The body's adaptive response to sustained calorie restriction, including reduced resting metabolic rate and increased appetite signaling, is well-established (Rosenbaum and Leibel, 2010, Journal of Clinical Investigation). This happens whether you're on a GLP-1 or not, though GLP-1 medications do suppress some of those compensatory hunger signals.

The creator's suggestion to talk to your provider about a dosage increase is appropriate advice. Dose titration is standard in GLP-1 protocols, and clinical trials for semaglutide and tirzepatide both used escalating dose schedules for this reason. What a provider decides to do depends on individual tolerance, side effects, and goals. That decision should not be made based on a TikTok video, including this one.

Resistance training, which the creator briefly mentions at the end, is arguably more important than any of these three tips for preserving metabolic rate during GLP-1-assisted weight loss. That point deserved more than a passing reference.